Who qualifies for setmelanotide?

Setmelanotide is approved only for patients with confirmed genetic variants causing POMC deficiency, PCSK1 deficiency, LEPR deficiency, or Bardet-Biedl syndrome. Genetic testing is required prior to initiation. It is not approved for common (polygenic) obesity. The drug is available through a restricted distribution program and specialty pharmacies.

Why does setmelanotide cause skin darkening?

MC4R is part of the melanocortin receptor family, which also includes MC1R — the receptor that regulates skin pigmentation. Setmelanotide has some cross-activity at MC1R, stimulating melanin production in skin and hair. This can cause generalized hyperpigmentation and darkening of existing moles (nevi). Patients require regular dermatologic monitoring.

Treatment hubFDA ApprovedDeep Dive

Setmelanotide Treatment Guide: Imcivree, Cost and Provider Paths

In the United States, Setmelanotide is an FDA-approved peptide therapy. Chronic weight management in adult and pediatric patients aged 6 years and older with obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.

Last reviewed: April 27, 2026

Overview

Setmelanotide is the first melanocortin-4 receptor (MC4R) agonist approved by the FDA for chronic weight management in patients with rare genetic obesity syndromes (POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome). It is the first obesity drug that targets the hypothalamic melanocortin pathway rather than the gut-brain axis.

Approved Product Paths

Imcivree

Branded setmelanotide pathway. Chronic weight management in adult and pediatric patients aged 6 years and older with obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome

Benefits

•First and only approved therapy for genetic MC4R-pathway obesity
•Dramatic weight loss (~25% body weight) in POMC/LEPR deficiency
•Reduces hunger and restores satiety signaling
•Improves quality of life and reduces comorbidities in rare obesity

Side Effects & Friction

•Injection site reactions (erythema, pruritus)
•Hyperpigmentation (skin darkening, including nevi)
•Nausea, vomiting, diarrhea
•Spontaneous penile erection in males

Administration Routes

Subcutaneous injection

Cost Reality

Setmelanotide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in weight loss who can evaluate whether Setmelanotide fits the patient's clinical profile and insurance constraints.

How Setmelanotide Works

Setmelanotide is an 8-amino-acid cyclic peptide melanocortin-4 receptor (MC4R) agonist. It is the first FDA-approved therapy for genetic obesity caused by POMC, PCSK1, or LEPR deficiencies.

Setmelanotide is a selective MC4R agonist designed to bypass upstream defects in the leptin-melanocortin signaling pathway. In patients with POMC, PCSK1, or LEPR mutations, the normal melanocortin pathway is disrupted, causing extreme hyperphagia and early-onset obesity.

MC4R activation in the hypothalamus reduces appetite, increases energy expenditure, and promotes weight loss. In patients with intact MC4R receptors but upstream pathway defects, setmelanotide directly activates the receptor and restores satiety signaling.

Unlike bremelanotide (another MC4R agonist), setmelanotide is highly selective for MC4R over MC1R, minimizing hyperpigmentation and tanning side effects.

The drug does not work in patients with MC4R receptor mutations because the drug requires an intact receptor to exert its effect. Genetic testing is mandatory before prescribing.

Setmelanotide is administered as a daily subcutaneous injection. Weight loss is typically rapid and substantial in responders, with hunger scores declining within weeks.

This is the first therapy to demonstrate that obesity can be treated at the genetic level by targeting specific molecular defects in appetite regulation pathways.

Melanocortin-4 receptor (MC4R)Hypothalamic POMC neuronsParaventricular nucleus

Clinical Trial Evidence

POMC/PCSK1 deficiency trial

Population: Patients with biallelic POMC or PCSK1 deficiency

N= 10

Duration: 52 weeks

Endpoint: Percent change in body weight

Mean weight loss: 23.1% at 52 weeks
Hunger scores reduced by >50%
All 10 patients achieved >10% weight loss
Rapid onset of effect within first 4 weeks

LEPR deficiency trial

Population: Patients with biallelic LEPR deficiency

N= 11

Duration: 52 weeks

Endpoint: Percent change in body weight

Mean weight loss: 9.7% at 52 weeks
Hunger scores significantly reduced
Effect less pronounced than in POMC deficiency but clinically meaningful
Response variable; some patients lost >20%

Dosing & Administration

Genetic obesity (POMC, PCSK1, LEPR deficiencies) (Imcivree)Subcutaneous · Once daily

Starting: 2 mg once daily

Titration: May increase to 3 mg after 2 weeks if tolerated

Maintenance: 2-3 mg once daily

Maximum: 3 mg once daily

•Inject subcutaneously into abdomen, thigh, or upper arm at same time each day
•Rotate injection sites
•Take without regard to meals
•Reconstitute with provided diluent; use within 30 days
•Must have confirmed genetic diagnosis before initiation

Side Effect Profile

Very common

Injection site reactionsmild45%

Erythema, pruritus, pain; usually mild

Hyperpigmentationmild40%

Darkening of skin and moles; MC1R effect at high doses

Nauseamild25%

Usually transient

Headachemild20%

Transient

Cardiovascular

Spontaneous penile erectionmoderate8%

MC4R activation effect; usually resolves with continued therapy

Sexual adverse reactionsmild5%

Include yawning and stretching (reported in some patients)

Other

Diarrheamild15%

Usually self-limiting

Fatiguemild10%

Mild

Contraindications & Warnings

Do Not Use

Confirmed MC4R mutation (drug will not work without intact receptor)
Pregnancy or breastfeeding
Known hypersensitivity to setmelanotide

Important Warnings

Genetic testing required before prescribing: must confirm biallelic POMC, PCSK1, or LEPR deficiency. Will not work in common polygenic obesity or MC4R mutations.
Hyperpigmentation: generalized darkening of skin and existing moles. Monitor for changes in nevi; rule out melanoma if suspicious changes occur.
Spontaneous erections in males: may be distressing; usually diminish with continued therapy.
Depression and suicidal ideation: monitor mental health, particularly in adolescents.
Not for use in general obesity population; only for ultra-rare genetic forms.

Drug Interactions

Drug	Interaction	Severity	Mechanism
None significant	Minimal interaction potential	minor	Peptide metabolized by proteolysis; not CYP-dependent

Monitoring Requirements

Weight and BMI every 4 weeks
Hunger/appetite scores at each visit
Skin examination for hyperpigmentation and nevus changes
Mental health screening (depression, suicidal ideation)
Fasting glucose and lipids periodically
Sexual adverse effects in males

How Setmelanotide Compares

Efficacy in genetic obesitySetmelanotide advantage

Setmelanotide: 23% weight loss (POMC deficiency)

Lifestyle intervention alone: Minimal effect

Genetic obesity is refractory to diet/exercise; setmelanotide is transformative

EfficacyBariatric surgery advantage

Setmelanotide: 23% weight loss

Bariatric surgery: 25-35% weight loss

Surgery may produce more weight loss but carries operative risk

IndicationMetreleptin (Myalept) advantage

Setmelanotide: POMC/PCSK1/LEPR deficiency

Metreleptin (Myalept): Generalized lipodystrophy

Different ultra-rare indications; both are precision therapies for metabolic genetic disorders

General obesitySemaglutide advantage

Setmelanotide: Only for genetic obesity

Semaglutide: Approved for general obesity

Setmelanotide is not indicated for common obesity

Evidence Quality Assessment

Overall Evidence Grade: B

A = Strong evidence from multiple large RCTs

Human RCTs: Moderate: Small trials (n=10-11) due to ultra-rare disease; well-controlled open-label studies

Long-term data: Limited: 52-week data; longer-term follow-up ongoing

Real-world evidence: Very limited: Ultra-rare population; limited registry data

Regulatory status: FDA-approved for obesity due to POMC, PCSK1, or LEPR deficiency in patients ≥6 years old

Is Setmelanotide Right for You?

Ideal Candidates

Patients with confirmed biallelic POMC, PCSK1, or LEPR deficiency and severe early-onset obesity
Patients with hyperphagia that is unresponsive to behavioral interventions
Children ≥6 years and adults with genetic diagnosis
Families seeking targeted therapy for monogenic obesity

Avoid

Common polygenic obesity without genetic defect
Confirmed MC4R mutation (drug will not work)
Pregnancy or planned pregnancy
Patients with history of melanoma or suspicious nevi
Patients expecting cosmetic weight loss rather than treatment of genetic disease

Use With Caution

History of depression or suicidal ideation
Multiple atypical moles
Adolescents (monitor growth and pubertal development)
Patients unable to perform daily injections

Cost & Insurance Deep Dive

List Price (Monthly)

~$15,000-$20,000/month

Cash-Pay Range

$15,000-$20,000/month

Insurance Coverage Rate

~70-80% with confirmed genetic diagnosis and prior auth

Prior Auth Likelihood

Extremely high; requires genetic testing documentation, specialist attestation, and often case-by-case review

Savings Programs

Rhythm Pharmaceuticals patient assistanceMay provide medication at no cost

Eligibility: Uninsured/underinsured with confirmed diagnosis

Case-by-case application

Copay assistanceMay reduce out-of-pocket to $0

Eligibility: Commercially insured

Not for government insurance

Cost-Effectiveness Notes

•Extremely high cost justified by ultra-rare indication and transformative efficacy
•Without treatment, patients may require bariatric surgery or develop severe comorbidities
•Annual cost exceeds $200,000; insurance coverage is essential
•Precision medicine pricing model for monogenic disease

Ready to find a setmelanotide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a setmelanotide provider

GLP-1 Support Essentials

Products to help manage side effects and optimize outcomes during treatment.

LMNT Electrolyte Packets

Sodium-focused electrolytes to prevent dehydration and fatigue common in early GLP-1 therapy.

$30–45View on Amazon

High-Protein Shakes (30g)

Convenient protein shakes to maintain muscle mass on reduced GLP-1 caloric intake.

$28–42View on Amazon

Metamucil Fiber Supplement

Soluble fiber powder to manage constipation and GI side effects during GLP-1 treatment.

$20–30View on Amazon

Vitamin B12 (Methylcobalamin 1000mcg)

GLP-1 agonists can reduce B12 absorption over time — methylcobalamin is the most bioavailable form.

$10–20View on Amazon

Ginger Chews for Nausea

Natural nausea relief for the dose-escalation adjustment period, particularly weeks 1–4.

$8–15View on Amazon

Unflavored Whey Protein Isolate

Preserve lean mass without excess carbs or calories when appetite is suppressed.

$35–60View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor weight, body composition, and nutrition to maximize results.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.